<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Access Maced J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Open Access Maced J Med Sci</journal-id><journal-title-group><journal-title>Open Access Macedonian Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="epub">1857-9655</issn><publisher><publisher-name>Republic of Macedonia</publisher-name><publisher-loc>ID Design 2012/DOOEL Skopje</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31949517</article-id><article-id pub-id-type="pmc">6953938</article-id><article-id pub-id-type="publisher-id">OAMJMS-7-3205</article-id><article-id pub-id-type="doi">10.3889/oamjms.2019.675</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science</subject></subj-group></article-categories><title-group><article-title>Effect of Levosimendan Compared to Conventional Inotropic Agents on Hemodynamics and Outcome in Patient with Poor LV Function Undergoing Cardiac Surgery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khaled</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Almogy</surname><given-names>Ahmad Naem</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Shehata</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Ragab</surname><given-names>Fahim</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Zeineldin</surname><given-names>Khaled</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Critical Care Medicine, Cairo University, Cairo, Egypt</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Ahmad Naem Almogy. Department of Critical Care Medicine, Cairo University, Cairo, Egypt. E-Mail: <email xlink:href="ahmadpeace385@yahoo.com">ahmadpeace385@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><day>15</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>14</day><month>8</month><year>2019</year></pub-date><volume>7</volume><issue>19</issue><fpage>3205</fpage><lpage>3210</lpage><history><date date-type="received"><day>25</day><month>6</month><year>2019</year></date><date date-type="rev-recd"><day>14</day><month>7</month><year>2019</year></date><date date-type="accepted"><day>15</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2019 Mahmoud Khaled, Ahmad Naem Almogy, Mohammed Shehata, Fahim Ragab, Khaled Zeineldin.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/CC BY-NC/4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)</license-p></license></permissions><abstract><sec id="st1"><title>BACKGROUND:</title><p>Patients undergoing heart surgery involving cardiopulmonary bypass (CPB) experience global myocardial ischemia with subsequent reperfusion which, despite cardioplegic protection, may result in different degrees of transient ventricular dysfunction. Levosimendan is a &#x0201c;calcium sensitisers&#x0201d;, it improves myocardial contractility by sensitising troponin C to calcium without increasing myocardial oxygen consumption and without impairing relaxation and diastolic function.</p></sec><sec id="st2"><title>AIM:</title><p>To evaluate the adding effect of a calcium sensitiser (levosimendan) compared to the conventional inotropic and vasoactive agent used in the patient with poor left ventricular function undergoing cardiac surgery on different measured hemodynamic variables and the effect on the outcome.</p></sec><sec id="st3"><title>METHODS:</title><p>It is prospective observational studies were patients were divided into 2 groups of 30 patients each. The first Group received conventional inotropic and vasoactive treatment at different doses, while the other group received levosimendan additionally at a loading dose of 6-12mic/kg according to mean arterial pressure over 0.5 hr followed by 24 hrs infusion at 0.05 to 0.2 mic/kg/min. Hemodynamic data were collected at the end and 30 minutes after CPB, after that at 6, 12, 24, and 36 hours post CPB. Mean arterial pressure (MAP), central venous pressure (CVP), heart rate (HR), mixed venous saturation (Svo2), and base deficit (BD) were measured.</p></sec><sec id="st4"><title>RESULTS:</title><p>Levosimendan had significantly improved postoperative hemodynamic values as in the mixed venous pressure at different times postoperative (p &#x0003c; 0.05), also the base deficit at different times postoperative (p &#x0003c; 0.05), while there was a significant reduction in systemic vascular resistance as decreased mean arterial pressure in levosimendan group compared to conventional group at 6hrs postoperative mean 77.50 &#x000b1; 10.81 vs 83.73 &#x000b1; 10.81 with (p = 0.029), and at 12 hrs postoperative mean 77.37 &#x000b1; 10.10vs 84.23 &#x000b1; 13.81 with (p = 0.032), and there was no significant difference in heart rate at different times postoperative between both groups (p &#x0003e; 0.05), while there was no significant effect on mortality between both groups (p = 0.781).</p></sec><sec id="st5"><title>CONCLUSION:</title><p>Levosimendan had improved hemodynamic parameters significantly with no effect on mortality compared to conventional inotropic agents in a patient with poor left ventricular function undergoing cardiac surgery.</p></sec></abstract><kwd-group><kwd>Levosimendan</kwd><kwd>Cardiopulmonary bypass (CPB)</kwd><kwd>Hemodynamics</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>Patients undergoing heart surgery involving cardiopulmonary bypass (CPB) experience global myocardial ischemia with subsequent reperfusion which, despite cardioplegic protection, may result in different degrees of transient ventricular dysfunction, also known as myocardial stunning in the immediate postoperative period [<xref rid="ref1" ref-type="bibr">1</xref>], [<xref rid="ref2" ref-type="bibr">2</xref>]. If severe enough, this dysfunction can cause postoperative low cardiac output syndrome, a complication with an estimated prevalence of about10% and a mortality of 17% [<xref rid="ref3" ref-type="bibr">3</xref>].</p><p>Pharmacological support, in the form of vasodilator and inotropic therapy, as well as mechanical support, such as intra-aortic balloon counterpulsation and ventricular assist devices, is often necessary to restore adequate tissue perfusion in the immediate postoperative period [<xref rid="ref2" ref-type="bibr">2</xref>]. Perioperatively, the most frequently used inotropes are beta-adrenergic and phosphodiesterase III inhibitors [<xref rid="ref4" ref-type="bibr">4</xref>], [<xref rid="ref5" ref-type="bibr">5</xref>], [<xref rid="ref6" ref-type="bibr">6</xref>].</p><p>Levosimendan is a recently introduced indicator, it belongs to a novel group of agents called calcium sensitisers, which increase the sensitivity of contractile proteins to calcium. The use of this agent in the treatment of decompensated heart failure is based on its dual mechanism of action. It improves myocardial contractility by sensitising troponin C to calcium without increasing myocardial oxygen consumption [<xref rid="ref7" ref-type="bibr">7</xref>] and without impairing relaxation and diastolic function [<xref rid="ref8" ref-type="bibr">8</xref>]. Also, it causes the opening of ATP-dependent potassium channels on smooth muscle fibres, which induces systemic, pulmonary and coronary vasodilatation and may offer cardioprotective effects during myocardial ischaemia [<xref rid="ref9" ref-type="bibr">9</xref>], [<xref rid="ref10" ref-type="bibr">10</xref>], [<xref rid="ref11" ref-type="bibr">11</xref>].</p><p>Furthermore, growing evidence from <italic>in vitro</italic> and <italic>in vivo</italic> studies indicates that, unlike other inotropes, levosimendan does not affect or even improves diastolic function in failing myocardium [<xref rid="ref12" ref-type="bibr">12</xref>], [<xref rid="ref13" ref-type="bibr">13</xref>], [<xref rid="ref14" ref-type="bibr">14</xref>], [<xref rid="ref15" ref-type="bibr">15</xref>].</p><p>We aimed to evaluate the adding effect of a calcium sensitiser (levosimendan) compared to the conventional inotropic and vasoactive agent used in the patient with poor left ventricular function undergoing cardiac surgery on different measured hemodynamic variables and the effect on the outcome.</p></sec><sec sec-type="method" id="sec1-2"><title>Patients and Method</title><p>Our study was a prospective observational study, conducted from the period of May 2016 to May 2017, in which patients admitted to the intensive care units following cardiac surgery in different cardiac surgery centres (Cardiothoracic Department, Cairo University and other cardiothoracic centres, Cairo, Egypt).</p><p>A total of 60 patients were enrolled in our study and were subsequently divided into two groups 30 patients each, group received conventional inotropic and vasoactive treatment, while the other group received levosimendan additionally at loading dose 6-12 mic/kg according to mean arterial pressure over 0.5 hr followed by 24 hrs infusion at 0.05 to 0.2 mic/kg/min. Hemodynamic data were collected at the end and 30 minutes after CPB, after that at 6, 12, 24 and 36 hours post CPB. Mean arterial pressure (MAP), central venous pressure (CVP), heart rate (HR), mixed venous saturation (Svo<sub>2</sub>) and base deficit (BD) were measured.</p><sec id="sec2-1"><title>Inclusion criteria</title><p>All patients with poor preoperative left ventricle function ejection fraction &#x0003c; 35% undergoing cardiac surgery for valvular, coronary bypass or aortic aneurysm repair.</p></sec><sec id="sec2-2"><title>Exclusion criteria</title><p>Patients with congenital heart disease.</p><p>Patients with allergy to levosimendan.</p><p>All patients enrolled in our study were subjected to:</p><p>
<list list-type="simple"><list-item><p>- Full history and clinical examination.</p></list-item><list-item><p>- Preoperative logistic EUROSCOREII evaluation.</p></list-item><list-item><p>- Laboratory investigation including:</p></list-item><list-item><p>- Complete blood count.</p></list-item><list-item><p>- Renal and liver function tests.</p></list-item><list-item><p>- Coagulation profile.</p></list-item><list-item><p>- Pre and postoperative echocardiography.</p></list-item><list-item><p>- Chest x-ray.</p></list-item><list-item><p>- ECG.</p></list-item></list>
</p></sec><sec id="sec2-3"><title>Statistical analysis</title><p>Data were collected, revised, coded and entered to the statistical package for social science (IBM SPSS) version 20. Qualitative data were presented as number and percentages, while quantitative data were presented as mean, standard deviations and ranges. The comparison between two groups with qualitative data was made by using <italic>Chi-square test</italic>, the comparison between two independent groups with quantitative data and parametric distribution was made by using <italic>Independent t-test</italic>, while the Mann Whitney test is done for two independent samples with nonparametric distribution and the comparison between more than two groups with quantitative data and parametric distribution was done by using One Way ANOVA test. The p-value was considered significant if &#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>Our study enrolled a total of 60 patients: 46 males (77%), 14 females (23%), who were admitted to ICU following cardiac surgery with preoperative echocardiography revealing impaired cardiac functions EF &#x0003c; 35%.</p><p>Demographic data were presented in <xref rid="T1" ref-type="table">Table 1</xref>. There was no significant statistical difference between both groups (p &#x0003e; 0.05) regarding age, gender, preoperative ejection fraction, while there was a significant statistical higher incidence of BMI, diabetes, hypertension in the levosimendan compared to conventional group (p = 0.001, 0.002, 0.005 respectively).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Study group demographic data</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" colspan="2" rowspan="3">Demographic data</th><th align="center" rowspan="1" colspan="1">Conventional group</th><th align="center" rowspan="1" colspan="1">Levosimendan group</th><th align="center" rowspan="3" colspan="1">P value</th></tr><tr><th align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">No. = 30</th><th align="center" rowspan="1" colspan="1">No. = 30</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">55.20 &#x000b1; 8.59</td><td align="center" rowspan="1" colspan="1">59.67 &#x000b1; 9.84</td><td align="center" rowspan="2" colspan="1">0-066</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">34 &#x02013; 72</td><td align="center" rowspan="1" colspan="1">30 &#x02013; 74</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">20 (66.7%)</td><td align="center" rowspan="1" colspan="1">26 (86.7%)</td><td align="center" rowspan="2" colspan="1">0-067</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">10 (33.3%)</td><td align="center" rowspan="1" colspan="1">4 (13.3%)</td></tr><tr><td align="left" rowspan="2" colspan="1">Body mass index</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">30.93 &#x000b1; 2.56</td><td align="center" rowspan="1" colspan="1">33.50 &#x000b1; 3.05</td><td align="center" rowspan="2" colspan="1">0-001</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">24 &#x02013; 36</td><td align="center" rowspan="1" colspan="1">29 &#x02013; 39</td></tr><tr><td align="left" rowspan="2" colspan="1">Diabetic</td><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">19 (63.3%)</td><td align="center" rowspan="1" colspan="1">7 (23.3%)</td><td align="center" rowspan="2" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">11 (36.7%)</td><td align="center" rowspan="1" colspan="1">23 (76.7%)</td></tr><tr><td align="left" rowspan="2" colspan="1">Hypertensive</td><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">28 (93.3%)</td><td align="center" rowspan="1" colspan="1">19 (63.3%)</td><td align="center" rowspan="2" colspan="1">0-005</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">2 (6.7%)</td><td align="center" rowspan="1" colspan="1">11 (36.7%)</td></tr><tr><td align="left" rowspan="2" colspan="1">Preoperative ejection Fraction</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">33.20 &#x000b1; 3.35</td><td align="center" rowspan="1" colspan="1">31.80 &#x000b1; 4.44</td><td align="center" rowspan="2" colspan="1">0.173</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">20 &#x02013; 36</td><td align="center" rowspan="1" colspan="1">20 &#x02013; 37</td></tr></tbody></table></table-wrap><sec id="sec2-4"><title>Heart Rate</title><p>There was no statistically significant difference regarding heart rate at any time postoperative between the two groups (p &#x0003e; 0.05) as presented in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap id="T2" position="float"><label>Table (2)</label><caption><p>Comparison of postoperative measured heart rate between both groups</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" colspan="2" rowspan="3">Heart rate</th><th align="center" rowspan="1" colspan="1">Conventional group</th><th align="center" rowspan="1" colspan="1">Levosimendan group</th><th align="center" rowspan="3" colspan="1">P-value</th></tr><tr><th align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">No. = 30</th><th align="center" rowspan="1" colspan="1">No. = 30</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Immediate postoperative</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">102.13 &#x000b1; 14.00</td><td align="center" rowspan="1" colspan="1">101.57 &#x000b1; 20.08</td><td align="center" rowspan="2" colspan="1">0.900</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">77 &#x02013; 132</td><td align="center" rowspan="1" colspan="1">65 &#x02013; 160</td></tr><tr><td align="left" rowspan="2" colspan="1">0.5hr postoperative</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">101.90 &#x000b1; 13.17</td><td align="center" rowspan="1" colspan="1">101.90 &#x000b1; 19.71</td><td align="center" rowspan="2" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">71 &#x02013; 124</td><td align="center" rowspan="1" colspan="1">76 &#x02013; 170</td></tr><tr><td align="left" rowspan="2" colspan="1">6hrs postoperative</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">101.73 &#x000b1; 12.67</td><td align="center" rowspan="1" colspan="1">99.17 &#x000b1; 18.94</td><td align="center" rowspan="2" colspan="1">0.540</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">71 &#x02013; 125</td><td align="center" rowspan="1" colspan="1">62 &#x02013; 146</td></tr><tr><td align="left" rowspan="2" colspan="1">12hrs postoperative</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">102.13 &#x000b1; 15.14</td><td align="center" rowspan="1" colspan="1">101.50 &#x000b1; 18.99</td><td align="center" rowspan="2" colspan="1">0.887</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">70 &#x02013; 139</td><td align="center" rowspan="1" colspan="1">73 &#x02013; 163</td></tr><tr><td align="left" rowspan="2" colspan="1">24hrs postoperative</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">102.90 &#x000b1; 15.83</td><td align="center" rowspan="1" colspan="1">106.33 &#x000b1; 20.72</td><td align="center" rowspan="2" colspan="1">0.474</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">75 &#x02013; 142</td><td align="center" rowspan="1" colspan="1">63 &#x02013; 150</td></tr><tr><td align="left" rowspan="2" colspan="1">36hrs postoperative</td><td align="left" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">97.33 &#x000b1; 18.96</td><td align="center" rowspan="1" colspan="1">107.37 &#x000b1; 23.67</td><td align="center" rowspan="2" colspan="1">0.075</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">60 &#x02013; 140</td><td align="center" rowspan="1" colspan="1">54 &#x02013; 170</td></tr></tbody></table></table-wrap></sec><sec id="sec2-5"><title>Mean arterial blood pressure</title><p>Regarding mean arterial pressure, there was a statistically significant difference between both groups at 6hrs postoperative wherein the conventional group mean arterial pressure was higher 83.73 &#x000b1; 10.81mmHg compared to the levosimendan group mean arterial pressure was 77.50 &#x000b1; 10.81 mmHg (p = 0.029).</p><p>Also, there was a statistically significant difference between both groups at 12 hrs postoperatively wherein the conventional group mean arterial pressure was higher 84.23 &#x000b1; 13.81 mmHg compared to the levosimendan group mean arterial pressure was 77.37 &#x000b1; 10.10 mmHg (p = 0.032). While there was no statistically significant difference at immediate, 0.5 hr, 24hrsand at 36hrs postoperatively (p &#x0003e; 0.05) as shown in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Mean arterial pressure between both groups (PO) postoperative; (#) significant P-value</p></caption><graphic xlink:href="OAMJMS-7-3205-g001"/></fig></sec><sec id="sec2-6"><title>Central venous pressure (CVP)</title><p>Regarding central venous pressure, there was statistically significant lower CVP at 6hrs postoperative in the conventional group with median 6.00 (3.00 &#x02013; 9.00) cm H2O compared to the levosimendan group median was10.00 (5.00 &#x02013; 12.00) cmH2O (p = 0.004). Also, there was statistically significant lower CVP at 12hrs postoperative in the conventional group with median 7.50 (4.00 &#x02013; 9.00) cmH2O compared to the levosimendan group median 10.00 (9.00 &#x02013; 13.00) cmH2O (p = 0.006).</p><p>There was no statistically significant difference at immediate, 0.5 hr, 24 hrs and 36 hrs postoperatively (P &#x0003e; 0.05) as shown in <xref ref-type="fig" rid="F2">Figure 2</xref>.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Central venous pressure between both groups (PO); postoperative (#) significant P-value</p></caption><graphic xlink:href="OAMJMS-7-3205-g002"/></fig></sec><sec id="sec2-7"><title>Base deficit</title><p>There was a highly statistically significant higher base deficit in the conventional group compared to the levosimendan group at immediate, 0.5 hr, 6 hrs, 24 hrs and 36 hrs postoperatively (p = 0.001, 0.001, 0.009, 0.021 and 0.001) respectively. While there was no statistically significant difference in the base deficit between both groups at 12 hrs postoperatively (p = 0.104) as shown in <xref ref-type="fig" rid="F3">Figure 3</xref>.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Base deficit between both groups (PO) postoperative; (#) significant P-value</p></caption><graphic xlink:href="OAMJMS-7-3205-g003"/></fig></sec><sec id="sec2-8"><title>Mixed venous oxygen saturation</title><p>There was a highly statistically significant higher mixed venous oxygen saturation in the levosimendan group compared to the conventional group at immediate, 0.5 hr, 6 hrs, 12 hrs, 24 hrs and 36hrs postoperatively (p = 0.013, 0.015, 0.032, 0.024, 0.005 and 0.011) respectively as shown in <xref ref-type="fig" rid="F4">Figure 4</xref>.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Mixed venous pressure between both groups</p></caption><graphic xlink:href="OAMJMS-7-3205-g004"/></fig></sec><sec id="sec2-9"><title>Outcome</title><p>Postoperative ejection fraction was significantly higher in the levosimendan group than the conventional group (p = 0.002), length of hospital stay was significantly lower in the levosimendan group than in conventional group (p = 0.028). Also, there was a statistically significant higher logistic EUROSCOREII in the levosimendan group than in the conventional group (p = 0.046) as presented in <xref rid="T3" ref-type="table">Table 3</xref>.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Outcomes in the conventional and levosimendan group</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" colspan="2" rowspan="3">Outcomes</th><th align="center" rowspan="1" colspan="1">Conventional group</th><th align="center" rowspan="1" colspan="1">Levosimendan group</th><th align="center" rowspan="3" colspan="1">P value</th></tr><tr><th align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">No. = 30</th><th align="center" rowspan="1" colspan="1">No. = 30</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Postoperative ejection fraction</td><td align="center" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">33.73 &#x000b1; 2.96</td><td align="center" rowspan="1" colspan="1">36.90 &#x000b1; 4.53</td><td align="center" rowspan="2" colspan="1">0.002</td></tr><tr><td align="center" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">25 &#x02013; 39</td><td align="center" rowspan="1" colspan="1">25 &#x02013; 44</td></tr><tr><td align="left" rowspan="2" colspan="1">Mechanical ventilation duration in hours</td><td align="center" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">51.43 &#x000b1; 66.29</td><td align="center" rowspan="1" colspan="1">43.27 &#x000b1; 36.48</td><td align="center" rowspan="2" colspan="1">0.557</td></tr><tr><td align="center" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">6 &#x02013; 288</td><td align="center" rowspan="1" colspan="1">6 &#x02013; 120</td></tr><tr><td align="left" rowspan="2" colspan="1">Length of ICU stay in days</td><td align="center" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">4.03 &#x000b1;2.71</td><td align="center" rowspan="1" colspan="1">3.27 &#x000b1; 1.68</td><td align="center" rowspan="2" colspan="1">0.193</td></tr><tr><td align="center" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">2 &#x02013; 12</td><td align="center" rowspan="1" colspan="1">2 &#x02013; 8</td></tr><tr><td align="left" rowspan="2" colspan="1">Length of hospital stay in days</td><td align="center" rowspan="1" colspan="1">Mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">15.43 &#x000b1; 9.70</td><td align="center" rowspan="1" colspan="1">10.87 &#x000b1; 5.41</td><td align="center" rowspan="2" colspan="1"><bold>0.028</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">5 &#x02013; 46</td><td align="center" rowspan="1" colspan="1">5 &#x02013; 29</td></tr><tr><td align="left" rowspan="2" colspan="1">Logistic EUROSCOREII</td><td align="center" rowspan="1" colspan="1">Median (IQR)</td><td align="center" rowspan="1" colspan="1">1.88 (1.20 &#x02013; 3.57)</td><td align="center" rowspan="1" colspan="1">3.19 (1.76 &#x02013; 6.70)</td><td align="center" rowspan="2" colspan="1">0.046</td></tr><tr><td align="center" rowspan="1" colspan="1">Range</td><td align="center" rowspan="1" colspan="1">0.76 &#x02013; 21.06</td><td align="center" rowspan="1" colspan="1">0.68 &#x02013; 21.72</td></tr></tbody></table></table-wrap><p>There was no statistically significant difference between both groups regarding mortality with lower mortality in the levosimendan group 9 patients (30%) did not survive compared to conventional group were10 patients (33.3%) did not survive (p = 0.781) as presented in <xref rid="T4" ref-type="table">Table 4</xref>.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Mortality in the two study groups</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="3" colspan="1">Mortality</th><th align="center" rowspan="1" colspan="1">Conventional group</th><th align="center" rowspan="1" colspan="1">Levosimendan group</th><th align="center" rowspan="3" colspan="1">P-value</th></tr><tr><th align="center" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">No. = 30</th><th align="center" rowspan="1" colspan="1">No. = 30</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Survival Non survival</td><td align="center" rowspan="1" colspan="1">20 (66.7%)</td><td align="center" rowspan="1" colspan="1">21 (70.0%)</td><td align="center" rowspan="2" colspan="1">0.781</td></tr><tr><td align="center" rowspan="1" colspan="1">10 (33.3%)</td><td align="center" rowspan="1" colspan="1">9 (30.0%)</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>In our study using of levosimendan achieved statistically significant improvement in left ventricular function (EF%) postoperatively determined by echocardiography compared to conventional group (36.90 &#x000b1; 4.53 VS 33.73 &#x000b1; 2.96), (p = 0.002).</p><p>Supporting our results Husedzinovic et al., [<xref rid="ref16" ref-type="bibr">16</xref>] in a double-blind, randomised trial evaluating the effect of levosimendan as a new strategy during off-pump coronary artery bypass grafting enrolling 24 patients received either placebo or levosimendan at a dose of 12 mic/kg as an infusion for 15 min before CABG. At 10 min and 60 min post-infusion, the cardiac index and the LVEF were significantly higher with levosimendan than with placebo (P = 0.018 each). The stroke volume index was significantly higher for levosimendan at 10 min (P = 0.018), but not at 60 min (P = 0.063).</p><p>In concordance to our study, Barisin S et al., [<xref rid="ref17" ref-type="bibr">17</xref>] in his study levosimendan in off-pump coronary artery bypass: a Four-time masked, controlled study enrolling 31 patients: 10 patients received a high dose,10 patients received a low dose, and 11 patients received a placebo.</p><p>Two dose schedules: low dose(12 mic/kg), high dose (24 mic/kg) over 10min; treatment was given 20min before start of surgery result in significant increases in cardiac output and LVEF occurred after high-dose (P = 0.001; P = 0.006) and low-dose levosimendan (P = 0.001; P = 0.002). Both levosimendan doses produced significant increased stroke volume and decreased systemic vascular resistance.</p><p>In our study, the heart rate showed no significant statistical difference at all times postoperative between both groups (p &#x0003e; 0.05).</p><p>This went side by side with Stefan G. DeHert et al., [<xref rid="ref18" ref-type="bibr">18</xref>] who conducted a study enrolling 30 patients evaluating the effects of levosimendan in cardiac surgery patients with poor left ventricular function had found that there was no statistically difference in the heart rate at all times postoperatively between both groups (p &#x0003e; 0.05).</p><p>Also, Polychronis Malliotakis et al., [<xref rid="ref19" ref-type="bibr">19</xref>] who conducted a study enrolling12 patients evaluating the hemodynamic effects of levosimendan for low cardiac output after cardiac surgery had determined that there were no significant changes in heart rate postoperatively (p &#x0003e; 0.05).</p><p>In contrast, Ravikumar Gandham et al., [<xref rid="ref20" ref-type="bibr">20</xref>] who conducted a study enrolling 60 patients evaluating a comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair/replacement for severe mitral stenosis had found that there was a significant difference in heart rate being higher in the conventional group at mostly all times postoperatively (p &#x0003c; 0.05) this variance may be due to that he was mainly comparing dobutamine with levosimendan.</p><p>In our recent study, the mean arterial pressure was statistically significant at 6 and 12 hrs postoperatively (p = 0.029 and 0.032 respectively) being higher in the conventional group than the levosimendan group.</p><p>This was concordance to Julian Alvarez et al., [<xref rid="ref21" ref-type="bibr">21</xref>] who conducted a study enrolling 50 patient evaluating the hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery had found that there was a significant mean arterial pressure difference between both groups at 6, 12, 24 and 48 hrs postoperatively (p &#x0003c; 0.05) being higher in the conventional group.</p><p>Polychronis Malliotakis et al., [<xref rid="ref19" ref-type="bibr">19</xref>] showed significance mean arterial pressure difference between both groups at 6 and 24 hrs postoperatively (p &#x0003c; 0.05) being higher in the conventional group.</p><p>Ravikumar Gandham et al., [<xref rid="ref20" ref-type="bibr">20</xref>] had found that significance means arterial pressure difference between both groups at immediate, 6 and 12 hrs postoperatively (p &#x0003c; 0.05) being higher in the conventional group.</p><p>Those agreements may be conducted to systemic and pulmonary vasodilator effect of levosimendan, leading to a reduction in blood pressure.</p><p>In our study, evaluating central venous pressure at 6 and 12 hrs postoperatively were statistically significant (p = 0.004 and 0.006 respectively) between both groups were lower in the conventional group.</p><p>In concordance to our results other studies like Julian Alvarez et al., [<xref rid="ref21" ref-type="bibr">21</xref>] had found that significant difference in central venous pressure at 6, 12, 24 and 48 hrs postoperatively between both groups with (p &#x0003c; 0.05).</p><p>Polychronis Malliotakis et al. determined that there was a significant difference in central venous pressure at 6, 12 and 24 hrs postoperatively from baseline levosimendan infusion (p &#x0003c; 0.05).</p><p>Ravikumar Gandham et al., [<xref rid="ref20" ref-type="bibr">20</xref>] found that there was a significant difference in central venous pressure at immediate, 6 and 12 hrs postoperatively from baseline levosimendan infusion with (p &#x0003c; 0.05).</p><p>They all found that there was a significant reduction in central venous pressure in levosimendan group as a result of a reduction in systemic and pulmonary vascular resistance this variation from our study may be due to there was no fixed postoperative IV fluid protocol among our patients.</p><p>In the current work, we used base deficit and mixed venous saturation being an indicator for adequate cardiac output and tissue perfusion they were strongly significant at almost all times postoperatively more base deficit in the conventional group than levosimendan group and higher mixed venous saturation in the levosimendan group than conventional group (p &#x0003c; 0.05).</p><p>In concordance with other studies Julian Alvarez et al., [<xref rid="ref21" ref-type="bibr">21</xref>] showed that significant difference in mixed venous oxygen saturation at 6, 12, 24 and 48 hrs postoperatively between both groups with (p &#x0003c; 0.05).</p><p>Polychronis Malliotakis et al., [<xref rid="ref19" ref-type="bibr">19</xref>] determined that there was a significant difference in mixed venous oxygen saturation at 6, 12 and 24 hrs postoperatively from baseline levosimendan infusion (p &#x0003c; 0.05).</p><p>Also, E. Al shawaf et al., [<xref rid="ref22" ref-type="bibr">22</xref>] who conducted a study enrolling 30 cardiac surgery patients comparing levosimendan Vs milrinone in type2 diabetic patient with low LVEF undergoing elective coronary artery surgery found that there were significantly higher cardiac index and mixed venous oxygen saturation with levosimendan (p &#x0003c; 0.05), significantly lower pulmonary capillary wedge pressure, systemic vascular resistance and oxygen extraction ratios.</p><p>In our study, there was no statistically significant difference in mortality between the conventional and levosimendan groups (10 patients Vs 9 patients) with (p = 0.781).</p><p>Our results went hand by hand with Stefan G. DeHert et al., [<xref rid="ref18" ref-type="bibr">18</xref>], who showed a non-significant effect on mortality (p = 0.224).</p><p>Also, Rajendrah Mehta et al., [<xref rid="ref23" ref-type="bibr">23</xref>] in the mega trial levo.cts enrolled 880 patients evaluating the effect of levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass had found that levosimendan did not affect the primary outcome (mortality) (p = 0.45). Other studies like Julian Alvarez et al., [<xref rid="ref21" ref-type="bibr">21</xref>], Polychronis Malliotakis et al., [<xref rid="ref19" ref-type="bibr">19</xref>], and Ravikumar Gandham et al., [<xref rid="ref20" ref-type="bibr">20</xref>] they were focusing mainly on the hemodynamic effect of levosimendan.</p><p><italic>Limitation:</italic> The present study has the following limitations:</p><p>
<list list-type="order"><list-item><p>The small number of patients was a certainly serious drawback.</p></list-item><list-item><p>Presence of several confounding factors (e.g. mode and parameters of mechanical ventilation, amount of fluids or blood products infused during the observation period).</p></list-item><list-item><p>Lack of invasive cardiac function monitoring (cardiac index, stroke volume index, systemic and pulmonary vascular resistance) that might have affected our results cannot be ruled out.</p></list-item><list-item><p>The infusion of the drug beyond 36hours, particularly in the subgroup with low cardiac output syndrome, will not be addressed in the study. As we seek to evaluate the efficacy of levosimendan on the short and intermediate-term outcomes in patients undergoing high-risk cardiac surgery on CPB and will be unable to provide insights into the long-term efficacy of the drug.</p></list-item></list>
</p><p>In conclusion:</p><p>
<list list-type="simple"><list-item><p>- Significant improvement in postoperative ejection fraction in the group receiving levosimendan (p = 0.002) and significant decrease in-hospital stay (p = 0.028).</p></list-item><list-item><p>- Significant improvement in hemodynamic parameters base deficit (p &#x0003c; 0.05) at almost all times postoperative, mixed venous Saturation (p &#x0003c; 0.05) at almost all times postoperative with no effect on heart rate (p &#x0003e; 0.05), with a mild reduction in mean arterial pressure due to inodilator effect of levosimendan.</p></list-item><list-item><p>- Levosimendan had no significant effect on mortality compared to the conventional group (p = 0.781).</p></list-item><list-item><p>- We recommend an increasing number of the study population, use fixed IV fluid protocol and more invasive cardiac function monitoring.</p></list-item></list>
</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Funding:</bold> This research did not receive any financial support</p></fn><fn fn-type="other"><p><bold>Competing Interests:</bold> The authors have declared that no competing interests exist</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breisblatt</surname><given-names>WM</given-names></name><name><surname>Stein</surname><given-names>KL</given-names></name><name><surname>Wolfe</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Acute myocardial dysfunction and recovery:a common occurrence after coronary bypass surgery</article-title><source>JAmCollCardiol</source><year>1990</year><volume>15</volume><fpage>1261</fpage><lpage>1269</lpage><comment>https://doi.org/10.1016/S0735-1097(10)80011-7</comment></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>AR</given-names></name><name><surname>Dhir</surname><given-names>AK</given-names></name><name><surname>Moors</surname><given-names>AH</given-names></name><name><surname>Latimer</surname><given-names>RD</given-names></name></person-group><article-title>Treatment of perioperative low cardiac output syndrome</article-title><source>The Annals of thoracic surgery</source><year>1995</year><volume>59</volume><fpage>S3</fpage><lpage>11</lpage><comment>https://doi.org/10.1016/0003-4975(94)00916-U</comment><pub-id pub-id-type="pmid">7840696</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>Ivanov</surname><given-names>J</given-names></name><name><surname>Weisel</surname><given-names>RD</given-names></name><name><surname>Ikonomidis</surname><given-names>JS</given-names></name><name><surname>Christakis</surname><given-names>GT</given-names></name><name><surname>David</surname><given-names>TE</given-names></name></person-group><article-title>Predictors of low cardiac output syndrome after coronary artery bypass</article-title><source>The Journal of thoracic and cardiovascular surgery</source><year>1996</year><volume>112</volume><issue>1</issue><fpage>38</fpage><lpage>51</lpage><comment>https://doi.org/10.1016/S0022-5223(96)70176-9</comment><pub-id pub-id-type="pmid">8691884</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butterworth</surname><given-names>JF</given-names></name><name><surname>Legault</surname><given-names>C</given-names></name><name><surname>Royster</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Factors that predict the use of positive inotropic drug support after cardiac valve surgery</article-title><source>Anesth Analg</source><year>1998</year><volume>86</volume><fpage>461</fpage><lpage>467</lpage><comment>https://doi.org/10.1213/00000539-199803000-00002 PMid:9495394</comment><pub-id pub-id-type="pmid">9495394</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romson</surname><given-names>JL</given-names></name><name><surname>Leung</surname><given-names>JM</given-names></name><name><surname>Bellows</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiacsurgical patients</article-title><source>Anesthesiology</source><year>1999</year><volume>91</volume><fpage>1318</fpage><lpage>1328</lpage><comment>https://doi.org/10.1097/00000542-199911000-00024 PMid:10551583</comment><pub-id pub-id-type="pmid">10551583</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>JH</given-names></name><name><surname>Bailey</surname><given-names>JM</given-names></name><name><surname>Deeb</surname><given-names>GM</given-names></name></person-group><article-title>Intravenous milrinone in cardiac surgery</article-title><source>The Annals of thoracic surgery</source><year>2002</year><volume>73</volume><issue>1</issue><fpage>325</fpage><lpage>30</lpage><comment>https://doi.org/10.1016/S0003-4975(01)02719-9</comment><pub-id pub-id-type="pmid">11834047</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figgitt</surname><given-names>DP</given-names></name><name><surname>Gillies</surname><given-names>PS</given-names></name><name><surname>Goa</surname><given-names>KL</given-names></name></person-group><source>Levosimendan drugs</source><year>2001</year><volume>61</volume><fpage>613</fpage><lpage>627</lpage><comment>https://doi.org/10.2165/00003495-200161050-00006 PMid:11368286</comment><pub-id pub-id-type="pmid">11368286</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>BF</given-names></name><name><surname>White</surname><given-names>CM</given-names></name></person-group><article-title>Levosimendan:implications for clinicians</article-title><source>The Journal of Clinical Pharmacology</source><year>2003</year><volume>43</volume><issue>10</issue><fpage>1071</fpage><lpage>81</lpage><comment>https://doi.org/10.1177/0091270003257217 PMid:14517189</comment><pub-id pub-id-type="pmid">14517189</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frishman</surname><given-names>WH</given-names></name></person-group><article-title>Advances in positive inotropic therapy:levosimendan</article-title><source>Critical care medicine</source><year>2003</year><volume>31</volume><issue>9</issue><fpage>2408</fpage><lpage>9</lpage><comment>https://doi.org/10.1097/01.CCM.0000084861.07091.F3 PMid:14501979</comment><pub-id pub-id-type="pmid">14501979</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehtonen</surname><given-names>L</given-names></name></person-group><article-title>Levosimendan a parenteral calcium-sensitising drug with additional vasodilatory properties</article-title><source>Expert Opin Investig Drugs</source><year>2001</year><volume>10</volume><fpage>955</fpage><lpage>970</lpage><comment>https://doi.org/10.1517/13543784.10.5.955 PMid:11322869</comment></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kersten</surname><given-names>JR</given-names></name><name><surname>Montgomery</surname><given-names>MW</given-names></name><name><surname>Pagel</surname><given-names>PS</given-names></name></person-group><article-title>Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels</article-title><source>AnesthAnalg</source><year>2000</year><volume>90</volume><fpage>5</fpage><lpage>11</lpage><comment>https://doi.org/10.1097/00000539-200001000-00003 PMid:10624967</comment></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>P M L</given-names></name><name><surname>Datz</surname><given-names>N</given-names></name><name><surname>Zeitz</surname><given-names>O</given-names></name><etal/></person-group><article-title>Levosimendan improves diastolic and systolic function in failing human myocardium</article-title><source>Eur J Pharmacol</source><year>2000</year><volume>404</volume><fpage>191</fpage><lpage>199</lpage><comment>https://doi.org/10.1016/S0014-2999(00)00609-9</comment><pub-id pub-id-type="pmid">10980279</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De</surname><given-names>Luca L</given-names></name><name><surname>Sardella</surname><given-names>G</given-names></name><name><surname>Proietti</surname><given-names>P</given-names></name><name><surname>Battagliese</surname><given-names>A</given-names></name><name><surname>Benedetti</surname><given-names>G</given-names></name><name><surname>Di</surname><given-names>Roma A</given-names></name><name><surname>Fedele</surname><given-names>F</given-names></name></person-group><article-title>Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction:a Doppler echocardiographic study</article-title><source>Journal of the American Society of Echocardiography</source><year>2006</year><volume>19</volume><issue>2</issue><fpage>172</fpage><lpage>7</lpage><comment>https://doi.org/10.1016/j.echo.2005.08.016 PMid:16455421</comment><pub-id pub-id-type="pmid">16455421</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parissis</surname><given-names>JT</given-names></name><name><surname>Panou</surname><given-names>F</given-names></name><name><surname>Farmakis</surname><given-names>D</given-names></name><name><surname>Adamopoulos</surname><given-names>S</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Paraskevaidis</surname><given-names>I</given-names></name><name><surname>Venetsanou</surname><given-names>K</given-names></name><name><surname>Lekakis</surname><given-names>J</given-names></name><name><surname>Kremastinos</surname><given-names>DT</given-names></name></person-group><article-title>Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure</article-title><source>The American journal of cardiology</source><year>2005</year><volume>96</volume><issue>3</issue><fpage>423</fpage><lpage>6</lpage><comment>https://doi.org/10.1016/j.amjcard.2005.03.092 PMid:16054474</comment><pub-id pub-id-type="pmid">16054474</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Givertz</surname><given-names>MM</given-names></name><name><surname>Andreou</surname><given-names>C</given-names></name><name><surname>Conrad</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Direct myocardial effects of levosimendan in humans with left ventricular dysfunction:Alteration of force-frequency and relaxation-frequency relationships</article-title><source>Circulation</source><year>2007</year><volume>115</volume><fpage>1218</fpage><lpage>1224</lpage><comment>https://doi.org/10.1161/CIRCULATIONAHA.106.668640 PMid:17339544</comment><pub-id pub-id-type="pmid">17339544</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonicki</surname><given-names>RM</given-names></name></person-group><article-title>Levosimendan as a new strategy during off-pump coronary artery bypass grafting:double-blind randomized placebo-controlled trial</article-title><source>Croat Med J</source><year>2005</year><volume>46</volume><issue>6</issue><fpage>950</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16342349</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barisin</surname><given-names>S</given-names></name><name><surname>Husedzinovic</surname><given-names>I</given-names></name><name><surname>Sonicki</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Levosimendan in off-pump coronary bypass:a four times masked controlled study</article-title><source>J Cardiovasc Pharmacol</source><year>2004</year><volume>44</volume><fpage>703</fpage><lpage>8</lpage><comment>https://doi.org/10.1097/00005344-200412000-00013 PMid:15550791</comment><pub-id pub-id-type="pmid">15550791</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Hert</surname><given-names>SG</given-names></name><name><surname>Lorsomradee</surname><given-names>S</given-names></name><name><surname>Cromheecke</surname><given-names>S</given-names></name><name><surname>Van der</surname><given-names>Linden PJ</given-names></name></person-group><article-title>The effects of levosimendan in cardiac surgery patients with poor left ventricular function</article-title><source>Anesthesia &#x00026;Analgesia</source><year>2007</year><volume>104</volume><issue>4</issue><fpage>766</fpage><lpage>73</lpage><comment>https://doi.org/10.1213/01.ane.0000256863.92050.d3 PMid:17377079</comment><pub-id pub-id-type="pmid">17377079</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malliotakis</surname><given-names>PO</given-names></name><name><surname>Xenikakis</surname><given-names>TH</given-names></name><name><surname>Linardakis</surname><given-names>MA</given-names></name><name><surname>Hassoulas</surname><given-names>JO</given-names></name></person-group><article-title>Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery:a case series</article-title><source>Hellenic J Cardiol</source><year>2007</year><volume>48</volume><issue>2</issue><fpage>80</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">17489345</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandham</surname><given-names>R</given-names></name><name><surname>Syamasundar</surname><given-names>A</given-names></name><name><surname>Ravulapalli</surname><given-names>H</given-names></name><name><surname>Karthekeyan</surname><given-names>RB</given-names></name><name><surname>Vakamudi</surname><given-names>M</given-names></name><name><surname>Kodalli</surname><given-names>R</given-names></name><name><surname>Nandipati</surname><given-names>S</given-names></name></person-group><article-title>A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair/ replacement in sever mitral stenosis</article-title><source>Ann Card Anaesth</source><year>2013</year><volume>16</volume><fpage>11</fpage><lpage>5</lpage><comment>https://doi.org/10.4103/0971-9784.105363 PMid:232&#x02204;0</comment><pub-id pub-id-type="pmid">23287080</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>J</given-names></name><etal/></person-group><article-title>evaluating the hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery</article-title><source>Rev EspCardiol</source><year>2006</year><volume>59</volume><issue>4</issue><fpage>338</fpage><lpage>45</lpage><comment>https://doi.org/10.1016/S1885-5857(06)60770-6</comment></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Shawaf</surname><given-names>E</given-names></name><name><surname>Ayed</surname><given-names>A</given-names></name><name><surname>Vislocky</surname><given-names>I</given-names></name><name><surname>Radomir</surname><given-names>B</given-names></name><name><surname>Dehrab</surname><given-names>N</given-names></name><name><surname>Tarazi</surname><given-names>R</given-names></name></person-group><article-title>Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery</article-title><source>Journal of cardiothoracic and vascular anesthesia</source><year>2006</year><volume>20</volume><issue>3</issue><fpage>353</fpage><lpage>7</lpage><comment>https://doi.org/10.1053/j.jvca.2006.02.012 PMid:16750735</comment><pub-id pub-id-type="pmid">16750735</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RH</given-names></name><name><surname>Leimberger</surname><given-names>JD</given-names></name><name><surname>van Diepen</surname><given-names>S</given-names></name><name><surname>Meza</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Jankowich</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>RW</given-names></name><name><surname>Hay</surname><given-names>D</given-names></name><name><surname>Fremes</surname><given-names>S</given-names></name><name><surname>Duncan</surname><given-names>A</given-names></name><name><surname>Soltesz</surname><given-names>EG</given-names></name></person-group><article-title>Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery</article-title><source>New England Journal of Medicine</source><year>2017</year><volume>376</volume><issue>21</issue><fpage>2032</fpage><lpage>42</lpage><comment>https://doi.org/10.1056/NEJMoa1616218 PMid:28316276</comment><pub-id pub-id-type="pmid">28316276</pub-id></element-citation></ref></ref-list></back></article>